Clinical trials: Healthcare-associated Pneumonia
VAP - Ventilator Associated Pneumonia
LUNG INFECTION IN ICU (LUNG-I3)
objective of LUNG-I3 study is to assess the quantitative and functional differences in cells between blood and bronchoalveolar lavage (BAL) fluid after an infection, with a special focus on alveolar macrophages and neutrophils
- Trial name
- LUNG-I3 (NCT06073834)
- Where
- France
- Volunteers
- 7 people
- Sponsor
- BioMérieux
Ventilator-associated Pneumonia
A Pharmacokinetic-pharmacodynamic Dose Comparison Study of 8 mg/kg of Inhaled or Parenteral Gentamicin in 12 Mechanically Ventilated Critically Ill Patients Treated for Ventilator-associated Pneumonia
Ventilator associated pneumonia (VAP) remains in the intensive care unit the infection associated with the highest morbidity and mortality. Respiratory infection with resistant organism are increasing in prevalence.
- Trial name
- GENTAERO (NCT02515448)
- Testing
- gentamicin
- Where
- 2 sites in France
- Volunteers
- 12 people
- Sponsor
- Poitiers University Hospital
Community Acquired Pneumonia
A Registry Study on Hospitalized Patients With Community-acquired Pneumonia in Real-life of China
The purpose of this study is to evaluate the disease burden of hospitalized patients with CAP and HCAP in real life of China
- Trial name
- CAP-China (NCT02492425)
- Where
- China
- Volunteers
- 3,000 people
- Sponsor
- Capital Medical University
Pneumonia, Bacterial, Nosocomial Infection
A Study of the Safety and Effectiveness of Doripenem in Filipino Patients With Nosocomial Pneumonia, Complicated Intra-Abdominal Infections and Complicated Urinary Tract Infections
The purpose of this study is to assess the safety and effectiveness of doripenem treatment among Filipino patients with nosocomial pneumonia, complicated intra-abdominal infections, and complicated urinary tract infection.
- Conditions
- Pneumonia, Bacterial, Nosocomial Infection, Intraabdominal Infections, Urinary Tract Infection
- Trial name
- NCT01763008
- Testing
- No intervention
- Where
- 4 sites in Philippines
- Volunteers
- 170 people
- Sponsor
- Janssen Pharmaceutica
Ventilator-associated Pneumonia
Prognosis and Virulence Determination of Capsule and Endotoxin During Klebsiella Spp. Ventilator-associated Pneumonias
Ventilator-associated pneumonia is the leading cause of nosocomial infection in the ICU. The pathogens responsible are multiple, but enterobacteria constitute a major source of pathogens involved.
- Trial name
- PROVIDENCE (NCT05450796)
- Where
- France
- Volunteers
- 1,000 people
- Sponsor
- Fondation Hôpital Saint-Joseph
Ventilator-Associated Pneumonia (VAP), Neonatal, Bronchopulmonary Dysplasia (BPD)
National Surveillance and Prevention of Neonatal VAP
The goal of this observational study is to improve how hospital-acquired lung infections (called ventilator-associated pneumonia, or VAP) are diagnosed, treated and prevented in very low birth weight (VLBW) infants, babies born…
- Conditions
- Ventilator-Associated Pneumonia (VAP), Neonatal, Bronchopulmonary Dysplasia (BPD), Antibiotic-Resistant Organisms (AROs), Health-Care Associated Infection (HAI)
- Trial name
- NCT07109791
- Where
- Canada
- Volunteers
- 1,500 people
- Sponsor
- University of Alberta
Pneumonia, Community Acquired Pneumonia
Targeting Platelet-Leukocyte Aggregates in Pneumonia With Ticagrelor
The hypothesis to be tested is that ticagrelor (Brilinta™) will reduce platelet activation and markers of inflammation in patients with pneumonia.
- Conditions
- Pneumonia, Community Acquired Pneumonia, Hospital Acquired Pneumonia, Acute Lung Injury
- Trial name
- XANTHIPPE (NCT01883869)
- Testing
- ticagrelor
- Where
- 2 sites in United States
- Volunteers
- 60 people
- Sponsor
- University of Kentucky
Hospital Acquired Pneumonia, Ventilator Acquired Pneumonia
Real-World Study of Ceftazidime Avibactam in China
This observational study will enroll approximately 450 in patients. Patients treated with CAZ AVI for at least 1 dose at around 20 research centers in China will be enroll.
- Conditions
- Hospital Acquired Pneumonia, Ventilator Acquired Pneumonia, Complicated Intra Abdominal Infections
- Trial name
- REACT (NCT05487586)
- Testing
- ceftazidime avibactam group
- Where
- 17 sites in China
- Volunteers
- 220 people
- Sponsor
- Pfizer
Mechanical Ventilation Complication
National Approach to Standardize and Improve Mechanical Ventilation
This is a pre-post implementation cohort study. This is a data driven quality improvement project which aims to improve the care of mechanically ventilated patients through the implementation of a bundle of evidence based…
- Trial name
- NASAM (NCT03790150)
- Testing
- Evidence-based practices
- Where
- 2 sites in Saudi Arabia
- Volunteers
- 27,966 people
- Sponsor
- King Abdullah International Medical Research Center
Ventilator Associated Pneumonia
Usage of Meropenem/Gentamicin Versus Ceftazidime/Avibactam in ARDS
This was a prospective double blind study conducted on 200 polytrauma patients admitted to King Abdul-Aziz Specialized Hospital, Taif, KSA between July 2018 and December 2019 in surgical ICU.
- Trial name
- NCT04402359
- Testing
- meropenem, ceftazidime 2 grams and avibactam 500, ventilator
- Where
- Saudi Arabia
- Volunteers
- 200 people
- Sponsor
- King Abdul Aziz Specialist Hospital
Ventilator Associated Pneumonia, Brain Injuries
M-I/E for Preventing VAP in Post-neurosurgical Patients
Ventilator-associated pneumonia (VAP) is a common infection in critically ill patients, especially those with acute brain injuries, leading to increased mortality and longer ICU stays.
- Conditions
- Ventilator Associated Pneumonia, Brain Injuries, Mechanical Insufflation-exsufflation
- Trial name
- NCT06511986
- Where
- China
- Volunteers
- 210 people
- Sponsor
- Beijing Sanbo Brain Hospital
Ventilator-Associated Pneumonia
The Pharmacodynamics of Meropenem in Patient With Ventilator-associated Pneumonia
The study was a randomized three-way crossover study. Each subject received meropenem in three regimens at room temperature consecutively: (i) bolus injection of 1 g of meropenem over 10 min every 8 h for 24 h, (ii) 3-h infusion…
- Trial name
- NCT02615041
- Testing
- Meropenem
- Where
- Thailand
- Volunteers
- 9 people
- Sponsor
- Sutep Jaruratanasirikul